In:
Diseases of the Esophagus, Oxford University Press (OUP), Vol. 36, No. Supplement_2 ( 2023-08-30)
Abstract:
The results of the CROSS trial has increased the impetus towards using neoadjuvant chemoradiation followed by surgery (trimodal) treatment for resectable stage II/III esophageal cancer. We sought to see what the Singaporean results have been based on data kept by the Singapore Cancer Registry. Methods Singapore Cancer Registry data pertaining to patients diagnosed with esophageal cancer from January 2010 to December 2017 were analysed in terms of trimodal treatment with curative intent. Results There were 840 patients in the registry with esophageal cancer over the study time period. 171 patients elected to have no active treatment and had a median survival of 2.4 months. Of the remainder, there were 59 patients who underwent trimodal treatment with curative intent. Overall median survival was 4.5 years in this group. There were 11 adenocarcinomas and 48 squamous cell carcinomas. Five-year survival rate was 44%. Conclusions Based on our national registry data, patients selected for neoadjuvant chemoradiation, and who actually follow-through with surgery, have a similar survival time when compared to the findings reported in the CROSS study.
Type of Medium:
Online Resource
ISSN:
1120-8694
,
1442-2050
DOI:
10.1093/dote/doad052.005
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2023
detail.hit.zdb_id:
639470-X
detail.hit.zdb_id:
2004949-3
